Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.5%

48 terminated/withdrawn out of 416 trials

Success Rate

81.0%

-5.5% vs industry average

Late-Stage Pipeline

8%

33 trials in Phase 3/4

Results Transparency

3%

6 of 205 completed trials have results

Key Signals

92 recruiting6 with results26 terminated22 withdrawn

Enrollment Performance

Analytics

N/A
241(72.2%)
Phase 2
36(10.8%)
Phase 1
22(6.6%)
Phase 4
18(5.4%)
Phase 3
15(4.5%)
Early Phase 1
2(0.6%)
334Total
N/A(241)
Phase 2(36)
Phase 1(22)
Phase 4(18)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (416)

Showing 20 of 416 trials
NCT07645664Not ApplicableNot Yet Recruiting

Scar Management Through Serial Casting

Role: lead

NCT07629193Not Yet Recruiting

Liver Transplant for Hepatocellular Carcinoma

Role: collaborator

NCT07524985Not ApplicableRecruiting

Joint Effort 2.0 : Evaluation Among General Population

Role: lead

NCT06397326Not ApplicableCompleted

Sustainable and Healthy Return-to-Work Program - PRATICAdr 2.0

Role: collaborator

NCT05592938Not ApplicableRecruiting

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

Role: collaborator

NCT06051123Not ApplicableRecruiting

Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients

Role: lead

NCT06034847Not ApplicableWithdrawn

Treatment of Persistent Distal Occlusion After Successful Proximal Recanalization in Thrombectomy

Role: lead

NCT02987686Phase 1Completed

Topical Infliximab for Sterile Corneal Melt

Role: lead

NCT03041883Not ApplicableRecruiting

Corneal Collagen Crosslinking to Increase the Resistance of the Support Graft of the KPro Type I Against Corneal Melting

Role: lead

NCT06743555Phase 1Not Yet Recruiting

Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study

Role: lead

NCT05180994Phase 1Recruiting

Topical Infliximab in Eyes With Penetrating Keratoplasty

Role: lead

NCT04198740Recruiting

Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface

Role: lead

NCT04232982Not ApplicableRecruiting

The Role of Transscleral Cyclophotocoagulation in Patients Undergoing a Boston Keratoprosthesis

Role: lead

NCT04951804Not ApplicableRecruiting

EUS-CPN With and Without Bupivacaine

Role: lead

NCT03444948Not ApplicableSuspended

A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma

Role: lead

NCT07533253Not ApplicableNot Yet Recruiting

Rescue Distal Thrombectomy in Treatment for Persistent Distal Occlusions

Role: lead

NCT07196410Phase 1Recruiting

KAN-004 for Immune-Related Diarrhea or Colitis

Role: lead

NCT05465161Not ApplicableRecruiting

STING MARK Universal Fiducial Marker System

Role: lead

NCT05457699Phase 2Recruiting

Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)

Role: lead

NCT07354594Phase 2Not Yet Recruiting

External Beam and Radioligand Radiotherapy for mCRPC

Role: lead